The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches

[1]  J. Taylor-Cousar,et al.  CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis , 2023, The Lancet.

[2]  S. Birket,et al.  Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy. , 2023, The Lancet. Respiratory medicine.

[3]  J. Pilewski,et al.  Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective. , 2023, The Lancet. Respiratory medicine.

[4]  M. Ziehm,et al.  Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis , 2023, European Respiratory Journal.

[5]  B. Ramsey,et al.  Cystic Fibrosis: A Review. , 2023, JAMA.

[6]  Daiki Matsuda,et al.  Engineered tRNAs suppress nonsense mutations in cells and in vivo , 2023, Nature.

[7]  A. Healy,et al.  A novel thiol-saccharide mucolytic for the treatment of muco-obstructive lung diseases , 2023, European Respiratory Journal.

[8]  T. Liou,et al.  Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double-blind, placebo-controlled phase 1/2 clinical study. , 2023, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[9]  N. Jacquier,et al.  Recent advances in therapeutic targets identification and development of treatment strategies towards Pseudomonas aeruginosa infections , 2023, BMC Microbiology.

[10]  L. Hoffman,et al.  Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist , 2023, The Journal of clinical investigation.

[11]  M. Rosenfeld,et al.  Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del Allele , 2023, American journal of respiratory and critical care medicine.

[12]  P. Burgel,et al.  The French compassionate programme of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant , 2023, European Respiratory Journal.

[13]  P. Sosnay,et al.  Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials. , 2023, The Lancet. Respiratory medicine.

[14]  P. Burgel,et al.  Role of inhaled antibiotics in the era of highly effective CFTR modulators , 2023, European Respiratory Review.

[15]  J. Lueck,et al.  Gene, RNA, and ASO-based therapeutic approaches in Cystic Fibrosis. , 2023, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[16]  G. Criner,et al.  Cystic fibrosis transmembrane conductance regulator in COPD: a role in respiratory epithelium and beyond , 2022, European Respiratory Journal.

[17]  A. Ramalho,et al.  Patient-derived cell models for personalized medicine approaches in cystic fibrosis. , 2022, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[18]  J. Fothergill,et al.  Challenges and opportunities in the development of novel antimicrobial therapeutics for cystic fibrosis. , 2022, Journal of medical microbiology.

[19]  G. Cimino,et al.  Elexacaftor/tezacaftor/ivacaftor corrects monocyte microbicidal deficiency in cystic fibrosis , 2022, European Respiratory Journal.

[20]  T. Murray,et al.  Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis. , 2022, Clinics in chest medicine.

[21]  K. McCoy,et al.  Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor , 2022, European Respiratory Journal.

[22]  Jue Chen,et al.  Molecular Structures Reveal Synergistic Rescue of Δ508 CFTR by Trikafta Modulators , 2022, Science.

[23]  M. Amaral,et al.  Development of novel therapeutics for all individuals with CF (the future goes on). , 2022, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[24]  J. Davies,et al.  Progress in Respiratory Gene Therapy , 2022, Human gene therapy.

[25]  D. Prais,et al.  Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study , 2022, American journal of respiratory and critical care medicine.

[26]  P. Harrison CFTR RNA- and DNA-based therapies. , 2022, Current opinion in pharmacology.

[27]  J. Rommens,et al.  Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease , 2022, npj Genomic Medicine.

[28]  B. Fleischmann,et al.  A PI3Kγ mimetic peptide triggers CFTR gating, bronchodilation, and reduced inflammation in obstructive airway diseases , 2022, Science Translational Medicine.

[29]  L. Galietta TMEM16A (ANO1) as a therapeutic target in cystic fibrosis. , 2022, Current opinion in pharmacology.

[30]  E. Hoffman,et al.  Elastic mucus strands impair mucociliary clearance in cystic fibrosis pigs , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[31]  F. Zara,et al.  SLC26A9 as a Potential Modifier and Therapeutic Target in Cystic Fibrosis Lung Disease , 2022, Biomolecules.

[32]  D. Hill,et al.  Physiology and Pathophysiology of Human Airway Mucus. , 2022, Physiological reviews.

[33]  O. Sommerburg,et al.  Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles. , 2021, American journal of respiratory and critical care medicine.

[34]  R. Fischer,et al.  Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. , 2021, The Lancet. Respiratory medicine.

[35]  B. Kerem,et al.  Antisense oligonucleotide splicing modulation as a novel Cystic Fibrosis therapeutic approach for the W1282X nonsense mutation. , 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[36]  M. Gentzsch,et al.  Impact of Airway Inflammation on the Efficacy of CFTR Modulators , 2021, Cells.

[37]  J. Lueck,et al.  Efficient suppression of endogenous CFTR nonsense mutations using anticodon-engineered transfer RNAs , 2021, bioRxiv.

[38]  G. Koppelman,et al.  Functional Restoration of CFTR Nonsense Mutations in Intestinal Organoids. , 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[39]  D. Waltz,et al.  Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes. , 2021, The New England journal of medicine.

[40]  H. Clevers,et al.  Evaluating CRISPR-based prime editing for cancer modeling and CFTR repair in organoids , 2021, Life Science Alliance.

[41]  R. Green,et al.  A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion , 2021, Nature Communications.

[42]  J. Davies,et al.  Cystic fibrosis , 2021, The Lancet.

[43]  R. Gibson,et al.  A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele , 2021, American journal of respiratory and critical care medicine.

[44]  I. Baumann,et al.  Chronic Rhinosinusitis with Nasal Polyps is Associated with Impaired TMEM16A-mediated Epithelial Chloride Secretion. , 2021, The Journal of allergy and clinical immunology.

[45]  B. Kerem,et al.  Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849 + 10 kb C-to-T splicing mutation , 2021, bioRxiv.

[46]  S. McColley,et al.  Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype , 2021, Pediatric pulmonology.

[47]  T. Haverty,et al.  A Randomized, Double‐Blind, Placebo‐Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX‐02 in Healthy Subjects , 2021, Clinical pharmacology in drug development.

[48]  C. López-Otín,et al.  Hallmarks of Health , 2020, Cell.

[49]  L. Ostrowski,et al.  Secretory Cells Dominate Airway CFTR Expression and Function in Human Airway Superficial Epithelia. , 2020, American journal of respiratory and critical care medicine.

[50]  Adan Chari Jirmo,et al.  Rescue from Pseudomonas aeruginosa airway infection via stem cell transplantation. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[51]  Meilan K. Han,et al.  Mucus Plugs and Emphysema in the Pathophysiology of Airflow Obstruction and Hypoxemia in Smokers. , 2020, American journal of respiratory and critical care medicine.

[52]  E. Kerem ELX-02: an investigational read-through agent for the treatment of nonsense mutation-related genetic disease , 2020, Expert opinion on investigational drugs.

[53]  M. Griese,et al.  Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial , 2020, American journal of respiratory and critical care medicine.

[54]  Fabian J Theis,et al.  LifeTime and improving European healthcare through cell-based interceptive medicine , 2020, Nature.

[55]  A. O'donnell,et al.  Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. , 2020, The New England journal of medicine.

[56]  C. Verfaillie,et al.  Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis , 2020, European Respiratory Journal.

[57]  M. Mall ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies , 2020, European Respiratory Journal.

[58]  I. Heimbeck,et al.  Single dose escalation studies with inhaled POL6014, a potent novel selective reversible inhibitor of human neutrophil elastase, in healthy volunteers and subjects with cystic fibrosis. , 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[59]  H. Clevers,et al.  CRISPR-Based Adenine Editors Correct Nonsense Mutations in a Cystic Fibrosis Organoid Biobank. , 2020, Cell stem cell.

[60]  D. McAuley,et al.  Targeting Proteases in Cystic Fibrosis Lung Disease: Paradigms, Progress, and Potential. , 2020, American journal of respiratory and critical care medicine.

[61]  H. Danahay,et al.  TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis , 2020, American journal of respiratory and critical care medicine.

[62]  S. Rowe,et al.  Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications. , 2019, American journal of respiratory and critical care medicine.

[63]  V. Waters,et al.  Microbiology of Cystic Fibrosis Airway Disease , 2019, Seminars in Respiratory and Critical Care Medicine.

[64]  Gareth W. Hughes,et al.  The MUC5B mucin polymer is dominated by repeating structural motifs and its topology is regulated by calcium and pH , 2019, Scientific Reports.

[65]  C. Teneback,et al.  Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial , 2019, The Lancet.

[66]  L. Lands,et al.  Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. , 2019, The New England journal of medicine.

[67]  R. Boucher Muco‐Obstructive Lung Diseases , 2019, The New England journal of medicine.

[68]  D. Waltz,et al.  Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles , 2019, ERJ Open Research.

[69]  P. Negulescu,et al.  In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis , 2019, Science Translational Medicine.

[70]  Boya Wang,et al.  An Improved Inhaled Mucolytic to Treat Airway Muco‐obstructive Diseases , 2019, American journal of respiratory and critical care medicine.

[71]  J. Wallenburg,et al.  CFTR modulator theratyping: Current status, gaps and future directions. , 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[72]  A. Chang,et al.  Bronchiectasis , 2018, Nature Reviews Disease Primers.

[73]  A. Orth,et al.  Structure-guided combination therapy to potently improve the function of mutant CFTRs , 2018, Nature Medicine.

[74]  A. Balázs,et al.  Role of the SLC26A9 Chloride Channel as Disease Modifier and Potential Therapeutic Target in Cystic Fibrosis , 2018, Front. Pharmacol..

[75]  J. Lipuma,et al.  Cystic fibrosis respiratory microbiota: unraveling complexity to inform clinical practice , 2018, Expert review of respiratory medicine.

[76]  J. Lueck,et al.  Engineered transfer RNAs for suppression of premature termination codons , 2018, Nature Communications.

[77]  M. Gentzsch,et al.  Ion Channel Modulators in Cystic Fibrosis , 2018, Chest.

[78]  B. Tümmler,et al.  Effects of Lumacaftor‐Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis , 2018, American journal of respiratory and critical care medicine.

[79]  E. Hoffman,et al.  Infection Is Not Required for Mucoinflammatory Lung Disease in CFTR‐Knockout Ferrets , 2018, American journal of respiratory and critical care medicine.

[80]  M. Wolfgang,et al.  Initial acquisition and succession of the cystic fibrosis lung microbiome is associated with disease progression in infants and preschool children , 2018, PLoS pathogens.

[81]  I. Klimant,et al.  Airway surface liquid pH is not acidic in children with cystic fibrosis , 2017, Nature Communications.

[82]  A. Kicic,et al.  The potential of phage therapy in cystic fibrosis: Essential human-bacterial-phage interactions and delivery considerations for use in Pseudomonas aeruginosa-infected airways. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[83]  N. Rousselet,et al.  MicroRNA-9 downregulates the ANO1 chloride channel and contributes to cystic fibrosis lung pathology , 2017, Nature Communications.

[84]  R. Finkel,et al.  Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study , 2016, The Lancet.

[85]  A. Doherty,et al.  Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis , 2016, Thorax.

[86]  Garry R. Cutting,et al.  From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations , 2016, Molecular biology of the cell.

[87]  David K. Meyerholz,et al.  Airway acidification initiates host defense abnormalities in cystic fibrosis mice , 2016, Science.

[88]  B. Byrne,et al.  Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy , 2015, Annals of neurology.

[89]  T. Welte,et al.  Hypoxic epithelial necrosis triggers neutrophilic inflammation via IL-1 receptor signaling in cystic fibrosis lung disease. , 2015, American journal of respiratory and critical care medicine.

[90]  S. Hazen,et al.  Oxidation increases mucin polymer cross-links to stiffen airway mucus gels , 2015, Science Translational Medicine.

[91]  D. Meyerholz,et al.  Origins of cystic fibrosis lung disease. , 2015, The New England journal of medicine.

[92]  B. Marsland,et al.  Host–microorganism interactions in lung diseases , 2014, Nature Reviews Immunology.

[93]  S. Donaldson,et al.  Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressure. , 2014, The Journal of clinical investigation.

[94]  N. Pedemonte,et al.  Structure and function of TMEM16 proteins (anoctamins). , 2014, Physiological reviews.

[95]  Peter D Sly,et al.  Risk factors for bronchiectasis in children with cystic fibrosis. , 2013, The New England journal of medicine.

[96]  R. Moss Pitfalls of drug development: lessons learned from trials of denufosol in cystic fibrosis. , 2013, The Journal of pediatrics.

[97]  J. Sallenave,et al.  Neutrophil elastase degrades cystic fibrosis transmembrane conductance regulator via calpains and disables channel function in vitro and in vivo. , 2013, American journal of respiratory and critical care medicine.

[98]  Todd A. Durham,et al.  Long term effects of denufosol tetrasodium in patients with cystic fibrosis. , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[99]  D. Hill,et al.  A Periciliary Brush Promotes the Lung Health by Separating the Mucus Layer from Airway Epithelia , 2012, Science.

[100]  Hans Clevers,et al.  A functional CFTR assay using primary cystic fibrosis intestinal organoids , 2013, Nature Medicine.

[101]  M. Welsh,et al.  Reduced Airway Surface pH Impairs Bacterial Killing in the Porcine Cystic Fibrosis Lung , 2012, Nature.

[102]  S. Randell,et al.  Mucus clearance, MyD88-dependent and MyD88-independent immunity modulate lung susceptibility to spontaneous bacterial infection and inflammation , 2012, Mucosal Immunology.

[103]  K. Du,et al.  Correction of Both NBD1 Energetics and Domain Interface Is Required to Restore ΔF508 CFTR Folding and Function , 2012, Cell.

[104]  Philip J. Thomas,et al.  Requirements for Efficient Correction of ΔF508 CFTR Revealed by Analyses of Evolved Sequences , 2012, Cell.

[105]  J. Fahy,et al.  Airway mucus function and dysfunction. , 2010, The New England journal of medicine.

[106]  P. Quinton Role of epithelial HCO3⁻ transport in mucin secretion: lessons from cystic fibrosis. , 2010, American journal of physiology. Cell physiology.

[107]  Raymond Farley,et al.  Toward gene therapy for cystic fibrosis using a lentivirus pseudotyped with Sendai virus envelopes. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[108]  Roberto Ravazzolo,et al.  TMEM16A, A Membrane Protein Associated with Calcium-Dependent Chloride Channel Activity , 2008, Science.

[109]  P. Quinton Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis , 2008, The Lancet.

[110]  J. Riordan,et al.  CFTR function and prospects for therapy. , 2008, Annual review of biochemistry.

[111]  R. Kronmal,et al.  Association between pulmonary function and sputum biomarkers in cystic fibrosis. , 2007, American journal of respiratory and critical care medicine.

[112]  R. Boucher Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. , 2007, Annual review of medicine.

[113]  V. Bindokas,et al.  CFTR regulates phagosome acidification in macrophages and alters bactericidal activity , 2006, Nature Cell Biology.

[114]  Richard C Boucher,et al.  Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice , 2004, Nature Medicine.

[115]  B. Kerem,et al.  Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. , 2003, The New England journal of medicine.

[116]  S. Emerson,et al.  Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study , 2003, The Lancet.

[117]  Min Goo Lee,et al.  Aberrant CFTR-dependent HCO-3 transport in mutations associated with cystic fibrosis , 2001, Nature.

[118]  S. Randell,et al.  Evidence for Periciliary Liquid Layer Depletion, Not Abnormal Ion Composition, in the Pathogenesis of Cystic Fibrosis Airways Disease , 1998, Cell.

[119]  M. Welsh,et al.  Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis , 1993, Cell.

[120]  L. Cantley,et al.  Na+ transport in cystic fibrosis respiratory epithelia. Abnormal basal rate and response to adenylate cyclase activation. , 1986, The Journal of clinical investigation.

[121]  C. Goss,et al.  The future of cystic fibrosis care: a global perspective. , 2020, The Lancet. Respiratory medicine.

[122]  M. Corey,et al.  Correlating CFTR Function with Clinical Features to Inform Precision Treatment of Cystic Fibrosis , 2019 .

[123]  M. Welsh,et al.  Structure and function of the CFTR chloride channel. , 1999, Physiological reviews.